The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - ...

Q3 2025 Management View Jay Sidhu, Founder, Chairman & CEO, highlighted, "We experienced deposit-led growth in our balance ...

Q3 2025 Earnings Call Transcript October 23, 2025 TechnipFMC plc beats earnings expectations. Reported EPS is $0.732, ...

As someone with a sound scientific background, immersed in the technical side of this work, I’ve seen firsthand how the field ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Cells process dynamic signaling inputs to regulate fate decisions during development. While oscillations or waves in key developmental pathways, such as Wnt, have been widely observed, the principles ...

In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in ...

Scientists from the National University of Singapore (NUS) have discovered a simple DNA "switch" that helps tropical ...

Instead of starting with whole group instruction and then using small groups to intervene, teachers can use a targeted ...